US equities
|
MU
$877.55
▲+2.46%
NVDA
$210.96
▼-0.59%
SPCX
$147.49
▲+1.89%
AAPL
$347.73
▼-0.14%
TSLA
$372.22
▼-0.63%
SNDK
$1,238.03
▼-1.82%
META
$642.62
▼-0.96%
AMD
$516.79
▲+1.74%
MU
$877.55
▲+2.46%
NVDA
$210.96
▼-0.59%
SPCX
$147.49
▲+1.89%
AAPL
$347.73
▼-0.14%
TSLA
$372.22
▼-0.63%
SNDK
$1,238.03
▼-1.82%
META
$642.62
▼-0.96%
AMD
$516.79
▲+1.74%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Metagenomi Therapeutics, Inc. - Common Stock
(NQ:
MGX
)
0.8056
-0.0106 (-1.30%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 23, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Metagenomi Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
Next >
Metagenomi Therapeutics, Inc. to Participate in the Chardan 10th Annual Healthcare Conference
October 13, 2026
From
Metagenomi Therapeutics, Inc.
Via
GlobeNewswire
Metagenomi Therapeutics, Inc. to Present at the Wells Fargo 21st Annual Healthcare Conference
September 01, 2026
From
Metagenomi Therapeutics, Inc.
Via
GlobeNewswire
Metagenomi Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results
August 10, 2026
From
Metagenomi Therapeutics, Inc.
Via
GlobeNewswire
Prolynx Names Simon Harnest as Chief Financial Officer and Amer Mirza, PhD, as Chief Scientific Officer as It Advances Multi-Program Obesity and Metabolic Disease Portfolio
July 15, 2026
Appointments strengthen financial and scientific leadership to help advance multiple ultra-long-acting incretin and non-incretin therapies toward the clinic
From
ProLynx Inc.
Via
GlobeNewswire
Metagenomi Therapeutics, Inc. to Present at the Jefferies Global Healthcare Conference
May 28, 2026
From
Metagenomi Therapeutics, Inc.
Via
GlobeNewswire
Metagenomi Therapeutics Reports Business Updates and First Quarter 2026 Financial Results
May 11, 2026
From
Metagenomi Therapeutics, Inc.
Via
GlobeNewswire
Metagenomi Therapeutics, Inc. Announces Publication in Nature Structural & Molecular Biology Highlighting Proprietary Compact CRISPR Nuclease with Enhanced Genome Editing Efficiency
April 16, 2026
From
Metagenomi Therapeutics, Inc.
Via
GlobeNewswire
Metagenomi Therapeutics Reports Business Updates and Full Year 2025 Financial Results
March 05, 2026
From
Metagenomi, Inc.
Via
GlobeNewswire
Metagenomi Therapeutics, Inc. to Present at the 46th Annual TD Cowen Healthcare Conference
February 23, 2026
From
Metagenomi, Inc.
Via
GlobeNewswire
Metagenomi Announces Corporate Name Change to Metagenomi Therapeutics, Inc. and Highlights Recent Business Milestones and 2026 Corporate Outlook
January 12, 2026
From
Metagenomi, Inc.
Via
GlobeNewswire
Metagenomi to Present Preclinical Data Supporting New Collaboration Target of APOC3 with Ionis Pharmaceuticals at Upcoming Nature Conference
December 01, 2025
From
Metagenomi, Inc.
Via
GlobeNewswire
Metagenomi to Present at Jefferies Global Healthcare Conference in London
November 17, 2025
From
Metagenomi, Inc.
Via
GlobeNewswire
Metagenomi Prioritizes Hemophilia A Program, Lays Off 25% Workforce
↗
November 12, 2025
Metagenomi reports curative-level FVIII activity for MGX-001 in primates and plans IND filing in 2026, extending cash runway into late 2027.
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
↗
November 12, 2025
Via
Benzinga
These stocks are moving in today's after hours session
↗
November 11, 2025
The regular session of the US market on Tuesday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.
Via
Chartmill
12 Health Care Stocks Moving In Tuesday's After-Market Session
↗
November 11, 2025
Via
Benzinga
Metagenomi Reports Third Quarter 2025 Financial Results and Announces Strategic Pipeline Prioritization and Leadership Updates
November 11, 2025
From
Metagenomi, Inc.
Via
GlobeNewswire
Metagenomi Presents New Preclinical Data from MGX-001 Hemophilia A Program Supporting Advancement into Clinical Development
November 11, 2025
From
Metagenomi, Inc.
Via
GlobeNewswire
Metagenomi Inc (NASDAQ:MGX) Q2 2025 Earnings: Revenue Surpasses Estimates, Loss Narrower Than Expected
↗
August 12, 2025
Metagenomi Inc (NASDAQ:MGX) reported Q2 2025 earnings with revenue beating estimates at $8.51M and a narrower loss of -$0.54 per share. Shares dipped slightly amid investor caution over cash burn and...
Via
Chartmill
Metagenomi Reports Business Updates and Second Quarter 2025 Financial Results
August 12, 2025
From
Metagenomi, Inc.
Via
GlobeNewswire
Metagenomi Appoints Laurence Reid, PhD to its Board of Directors
August 11, 2025
Dr. Reid brings 30 years of experience in building biotech companies based on innovative scientific platforms and shaping pipeline and business strategy
From
Metagenomi, Inc.
Via
GlobeNewswire
Which stocks are gapping on Wednesday?
↗
July 09, 2025
The session on Wednesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.
Via
Chartmill
Sam Altman Says He 'Didn't Think' Elon Musk Would Abuse Government Power, Tesla CEO Hits Back With 'Scam Altman' Jibe
↗
June 20, 2025
OpenAI CEO Sam Altman regrets underestimating Elon Musk's potential abuse of power to block OpenAI's $500B Stargate deal. Tensions also rise with Microsoft.
Via
Benzinga
Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst
↗
June 18, 2025
Lilly's Verve acquisition lifts sentiment in gene editing stocks, with analysts calling it a strategic and timely move in a tough funding climate.
Via
Benzinga
Demystifying Metagenomi: Insights From 4 Analyst Reviews
↗
May 15, 2025
Via
Benzinga
Levi Strauss To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Thursday
↗
May 15, 2025
Via
Benzinga
Metagenomi Presents Data Highlighting Advancements in Next-Generation Genome Editing Technologies at ASGCT Annual Meeting 2025
May 14, 2025
From
Metagenomi, Inc.
Via
GlobeNewswire
Metagenomi Reports Business Updates and First Quarter 2025 Financial Results
May 13, 2025
From
Metagenomi, Inc.
Via
GlobeNewswire
Metagenomi to Present at Upcoming Scientific Meetings
May 02, 2025
From
Metagenomi, Inc.
Via
GlobeNewswire
Metagenomi Reports Business Updates and Full Year 2024 Financial Results
March 17, 2025
From
Metagenomi, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
Next >
